Recent Progress in MicroRNA Research for Prostate Cancer

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Sep 27

PMID 39331237

Authors

Fan Yuan

Yue Hu

Yanmei Lei

Lingna Jin

Affiliations

Soon will be listed here.

Abstract

In recent years, prostate cancer (PCa) has seen an increasing prevalence, particularly among middle-aged and older men, positioning it as a significant health concern. Current PCa screening predominantly utilizes prostate-specific antigen (PSA) testing, digital rectal examination (DRE), and the Gleason scoring system. However, these diagnostic methods can sometimes be imprecise. Research has identified that specific microRNAs (miRNAs) exhibit altered expression levels in PCa patients, suggesting their potential as biomarkers for both diagnosis and prognosis. Furthermore, advancements in integrating miRNAs with traditional Chinese medicine (TCM) have shown promising results in PCa treatment, potentially serving as micro-markers for TCM syndrome differentiation and treatment effectiveness. Recent developments in anti-cancer therapies that target miRNAs have also been implemented in clinical settings, laying the groundwork for personalized and precise treatment strategies for PCa. This review aims to summarize the expression patterns of miRNAs in PCa patients and explore their roles in the diagnosis, treatment, and prognosis of the disease.

References

Huang S, Wa Q, Pan J, Peng X, Ren D, Huang Y . Downregulation of miR-141-3p promotes bone metastasis via activating NF-κB signaling in prostate cancer. J Exp Clin Cancer Res. 2017; 36(1):173. PMC: 5716366. DOI: 10.1186/s13046-017-0645-7. View

Rouviere O, Puech P, Renard-Penna R, Claudon M, Roy C, Mege-Lechevallier F . Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2018; 20(1):100-109. DOI: 10.1016/S1470-2045(18)30569-2. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R . Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2014; 67(1):33-41. PMC: 4252606. DOI: 10.1016/j.eururo.2014.07.035. View

Hamid S, Donaldson I, Hu Y, Rodell R, Villarini B, Bonmati E . The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification. Eur Urol. 2018; 75(5):733-740. PMC: 6469539. DOI: 10.1016/j.eururo.2018.08.007. View

Chen P, Lin S, Tsai S . Complexity in regulating microRNA biogenesis in cancer. Exp Biol Med (Maywood). 2020; 245(5):395-401. PMC: 7082889. DOI: 10.1177/1535370220907314. View

Bertoli G, Cava C, Castiglioni I . MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer. Int J Mol Sci. 2016; 17(3):421. PMC: 4813272. DOI: 10.3390/ijms17030421. View

Hart M, Nolte E, Wach S, Szczyrba J, Taubert H, Rau T . Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. Mol Cancer Res. 2013; 12(2):250-63. DOI: 10.1158/1541-7786.MCR-13-0230. View

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

10.

Saini S, Majid S, Yamamura S, Tabatabai L, Suh S, Shahryari V . Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res. 2010; 17(16):5287-98. DOI: 10.1158/1078-0432.CCR-10-2619. View

11.

Kumari A, Yadav S, Yadav S . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2009; 75(1):1-18. DOI: 10.1016/j.colsurfb.2009.09.001. View

12.

Duan X, Liu X, Li Y, Cao Y, Silayiding A, Zhang R . MicroRNA-498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN. Kaohsiung J Med Sci. 2019; 35(11):659-671. DOI: 10.1002/kjm2.12108. View

13.

Bryzgunova O, Zaporozhchenko I, Lekchnov E, Amelina E, Konoshenko M, Yarmoschuk S . Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer. PLoS One. 2019; 14(4):e0215003. PMC: 6457524. DOI: 10.1371/journal.pone.0215003. View

14.

Roa W, Brunet B, Guo L, Amanie J, Fairchild A, Gabos Z . Identification of a new microRNA expression profile as a potential cancer screening tool. Clin Invest Med. 2010; 33(2):E124. DOI: 10.25011/cim.v33i2.12351. View

15.

Stylianopoulos T, Jain R . Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A. 2013; 110(46):18632-7. PMC: 3832007. DOI: 10.1073/pnas.1318415110. View

16.

Fazio S, Berti G, Russo F, Evangelista M, DAurizio R, Mercatanti A . The miR-28-5p Targetome Discovery Identified SREBF2 as One of the Mediators of the miR-28-5p Tumor Suppressor Activity in Prostate Cancer Cells. Cells. 2020; 9(2). PMC: 7072282. DOI: 10.3390/cells9020354. View

17.

Selth L, Townley S, Gillis J, Ochnik A, Murti K, Macfarlane R . Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer. 2011; 131(3):652-61. DOI: 10.1002/ijc.26405. View

18.

Partin A, Kattan M, Subong E, Walsh P, Wojno K, Oesterling J . Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277(18):1445-51. View

19.

Budakoti M, Panwar A, Molpa D, Singh R, Busselberg D, Mishra A . Micro-RNA: The darkhorse of cancer. Cell Signal. 2021; 83:109995. DOI: 10.1016/j.cellsig.2021.109995. View

20.

Schaefer A, Jung M, Mollenkopf H, Wagner I, Stephan C, Jentzmik F . Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2009; 126(5):1166-76. DOI: 10.1002/ijc.24827. View